A randomized, multinational, noninferiority, phase III trial to evaluate the safety and efficacy of BF-200 aminolaevulinic acid gel vs. methyl aminolaevulinate cream in the treatment of nonaggressive basal cell carcinoma with photodynamic therapy

British Journal of Dermatology

Volumn 179, Issue 2, 2018, Pages 309-319

  Morton, C A ^a   Dominicus, R ^b   Radny, P ^c   Dirschka, T ^d   Hauschild, A ^e   Reinhold, U ^f   Aschoff, R ^g   Ulrich, M ^h   Keohane, S ⁱ   Ekanayake Bohlig, S ^j   Ibbotson, S ^k   Ostendorf, R ^l   Berking, C ^m   Grone D ⁿ   Schulze, H J ^o   Ockenfels, H M ^p   Jasnoch, V ^q   Kurzen, H ^r   Sebastian, M ^r   Stege, H ^s   Staubach, P ^t   Gupta, G ^u   Hubinger F ^v   Ziabreva, I ^w   Schmitz, B ^x   Gertzmann, A ^x   Lubbert H ^x   Szeimies, R M ^y   more..

^a Stirling Royal Infirmary   (United Kingdom)

^b Proderma   (Germany)

^c Private Dermatological Practice   (Germany)

^d UNIVERSITY OF WITTEN HERDECKE   (Germany)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^f Medical Centre Bonn   (Germany)

^g UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^h Dermatologische Privatpraxis CMB Collegium Medicum Berlin GmbH   (Germany)

ⁱ ST MARY S HOSPITAL   (United Kingdom)

^j MensingDerma Research GmbH   (Germany)

^k UNIVERSITY OF DUNDEE   (United Kingdom)

^l ZENTderma   (Germany)

^m LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

ⁿ Dermatological Practice   (Germany)

^o Hornheide Specialist Hospital   (Germany)

^p Dermatology and Allergology Practice at the Clinical Centre Hanau   (Germany)

^q Focus Clinical Drug Development GmbH   (Germany)

^r Private Practice   (Germany)

^s Lippe Detmold Clinic   (Germany)

^t UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^u UNIVERSITY OF GLASGOW   (United Kingdom)

^v Private Practice   (Germany)

^w ACCOVION GMBH   (Germany)

^x Biofrontera Pharmaceuticals GmbH   (Germany)

^y Department of Dermatology and Allergology   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; AMINOLEVULINIC ACID METHYL ESTER; BF-200 ALA; METHYL 5-AMINOLEVULINATE; PHOTOSENSITIZING AGENT; SKIN CREAM;

ADULT; ARTICLE; BASAL CELL CARCINOMA; CLINICAL EVALUATION; CONTROLLED STUDY; CREAM; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; EFFICACY PARAMETERS; ERYTHEMA; FEMALE; FOLLOW UP; GEL; HUMAN; MAJOR CLINICAL STUDY; MALE; NANOEMULSION; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PHASE 3 CLINICAL TRIAL; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RED LIGHT; SKIN EDEMA; SKIN PAIN; TREATMENT RESPONSE; ADVERSE EVENT; AGED; CLINICAL TRIAL; COMPARATIVE STUDY; CUTANEOUS DRUG ADMINISTRATION; DRUG EFFECT; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PHOTOCHEMOTHERAPY; PROCEDURES; SKIN; SKIN TUMOR; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; AGED; AMINOLEVULINIC ACID; CARCINOMA, BASAL CELL; FEMALE; HUMANS; MALE; MIDDLE AGED; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; SKIN; SKIN CREAM; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 85044532949     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.16441     Document Type: Article

References (35)

1. LeBoit PE, Burg G, Weedon D, Sarasin A, eds. Pathology and Genetics of Skin Tumours. World Health Organization Classification of Tumours. Lyon: IARC Press, 2006
2. Walling HW, Fosko SW, Geraminejad PA et al. Aggressive basal cell carcinoma: presentation, pathogenesis, and management. Cancer Metastasis Rev 2004; 23:389–402
3. Trakatelli M, Ulrich C, del Marmol V et al. Epidemiology of nonmelanoma skin cancer (NMSC) in Europe: accurate and comparable data are needed for effective public health monitoring and interventions. Br J Dermatol 2007; 156 (Suppl. 3):1–7
4. Athas WF, Hunt WC, Key CR. Changes in nonmelanoma skin cancer incidence between 1977–1978 and 1998–1999 in Northcentral New Mexico. Cancer Epidemiol Biomarkers Prev 2003; 12:1105–8
5. Trakatelli M, Morton C, Nagore E et al. Update of the European guidelines for basal cell carcinoma management. Eur J Dermatol 2014; 24:312–29
6. Flohil SC, de Vries E, Neumann HA et al. Incidence, prevalence and future trends of primary basal cell carcinoma in the Netherlands. Acta Derm Venereol 2011; 91:24–30
7. Perera E, Gnaneswaran N, Staines C et al. Incidence and prevalence of non-melanoma skin cancer in Australia: a systematic review. Australas J Dermatol 2015; 56:258–67
8. Telfer NR, Colver GB, Morton CA. Guidelines for the management of basal cell carcinoma. Br J Dermatol 2008; 159:35–48
9. Dandurand M, Petit T, Martel P et al. Management of basal cell carcinoma in adults: clinical practice guidelines. Eur J Dermatol 2006; 16:394–401
10. Patel RV, Frankel A, Goldenberg G. An update on nonmelanoma skin cancer. J Clin Aesthet Dermatol 2011; 4:20–7
11. Roozeboom MH, Arits AH, Nelemans PJ, Kelleners-Smeets NW. Overall treatment success after treatment of primary superficial basal cell carcinoma: a systematic review and meta-analysis of randomized and non-randomized trials. Br J Dermatol 2012; 167:733–56
12. Morton CA, Whitehurst C, McColl JH et al. Photodynamic therapy for large or multiple patches of Bowen disease and basal cell carcinoma. Arch Dermatol 2001; 137:319–24
13. Blume JE, Oseroff AR. Aminolevulinic acid photodynamic therapy for skin cancers. Dermatol Clin 2007; 25:5–14
14. Roozeboom MH, Aardoom MA, Nelemans PJ et al. Fractionated 5-aminolevulinic acid photodynamic therapy after partial debulking versus surgical excision for nodular basal cell carcinoma: a randomized controlled trial with at least 5-year follow-up. J Am Acad Dermatol 2013; 69:280–7
15. Wang I, Bendsoe N, Klinteberg CA et al. Photodynamic therapy vs. cryosurgery of basal cell carcinomas: results of a phase III clinical trial. Br J Dermatol 2001; 144:832–40
16. Rhodes LE, de Rie MA, Leifsdottir R et al. Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy versus surgery for nodular basal cell carcinoma. Arch Dermatol 2007; 143:1131–6
17. Mosterd K, Thissen MR, Nelemans P et al. Fractionated 5-aminolaevulinic acid-photodynamic therapy vs. surgical excision in the treatment of nodular basal cell carcinoma: results of a randomized controlled trial. Br J Dermatol 2008; 159:864–70
18. Kuijpers DI, Thissen MR, Thissen CA, Neumann MH. Similar effectiveness of methyl aminolevulinate and 5-aminolevulinate in topical photodynamic therapy for nodular basal cell carcinoma. J Drugs Dermatol 2006; 5:642–5
19. Szeimies RM. Methyl aminolevulinate-photodynamic therapy for basal cell carcinoma. Dermatol Clin 2007; 25:89–94
20. Szeimies RM, Ibbotson S, Murrell DF et al. A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8–20 mm), with a 12-month follow-up. J Eur Acad Dermatol Venereol 2008; 22:1302–11
21. Maisch T, Santarelli F, Schreml S et al. Fluorescence induction of protoporphyrin IX by a new 5-aminolevulinic acid nanoemulsion used for photodynamic therapy in a full-thickness ex vivo skin model. Exp Dermatol 2010; 19:e302–5
22. Schmitz L, Novak B, Hoeh AK et al. Epidermal penetration and protoporphyrin IX formation of two different 5-aminolevulinic acid formulations in ex vivo human skin. Photodiagnosis Photodyn Ther 2016; 14:40–6
23. Rhodes LE, de Rie M, Enstrom Y et al. Photodynamic therapy using topical methyl aminolevulinate versus surgery for nodular basal cell carcinoma: results of a multicenter randomized prospective trial. Arch Dermatol 2004; 140:17–23
24. Basset-Seguin N, Ibbotson SH, Emtestam L et al. Topical methyl aminolaevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial. Eur J Dermatol 2008; 18:547–53
25. Foley P. Clinical efficacy of methyl aminolevulinate (Metvix) photodynamic therapy. J Dermatolog Treat 2003; 14(Suppl. 3):15–22
26. Kennedy JC, Pottier RH, Pross DC. Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. J Photochem Photobiol B 1990; 6:143–8
27. Schulten R, Novak B, Schmitz B, Lubbert H. Comparison of the uptake of 5-aminolevulinic acid and its methyl ester in keratinocytes and skin. Naunyn Schmiedebergs Arch Pharmacol 2012; 385:969–79
28. Agostinis P, Berg K, Cengel KA et al. Photodynamic therapy of cancer: an update. CA Cancer J Clin 2011; 61:250–81
29. Hurlimann AF, Hanggi G, Panizzon RG. Photodynamic therapy of superficial basal cell carcinomas using topical 5-aminolevulinic acid in a nanocolloid lotion. Dermatology 1998; 197:248–54
30. ® lamp. Br J Dermatol 2016; 175:696–705
31. Dirschka T, Radny P, Dominicus R et al. Long-term (6 and 12 months) follow-up of two prospective, randomized, controlled phase III trials of photodynamic therapy with BF-200 ALA and methyl aminolaevulinate for the treatment of actinic keratosis. Br J Dermatol 2013; 168:825–36
32. Dirschka T, Radny P, Dominicus R et al. Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a multicentre, randomized, observer-blind phase III study in comparison with a registered methyl-5-aminolaevulinate cream and placebo. Br J Dermatol 2012; 166:137–46
33. Peng Q, Warloe T, Berg K et al. 5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges. Cancer 1997; 79:2282–308
34. Arits AH, Mosterd K, Essers BA et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncol 2013; 14:647–54
35. Morton CA, Szeimies RM, Sidoroff A, Braathen LR. European guidelines for topical photodynamic therapy part 1: treatment delivery and current indications – actinic keratoses, Bowen's disease, basal cell carcinoma. J Eur Acad Dermatol Venereol 2013; 27:536–44